

Clinical Research at the NCI

Why I love working at the Disneyland of Clinical Research

Kate Lurain MD MPH

Assistant Research Physician

HIV and AIDS Malignancy Branch, CCR, NCI

Associate Program Director, NIH Hematology Oncology Fellowship Program

Two Institutes, One Fellowship




Fellowship Program

11 ACGME Fellows per Year

NIH Hematology Oncology Fellowship


ACGME Approved Size



156 ACGME accredited heme / onc fellowships in US.

Only MSK, B&W/MGH and MDA have similar / slightly more fellows

Fellowship Size





Dr. Krithika Shanmugasundaram



Dr. Bisi Lawal



Dr. Jamie Hur



Dr. Thomas Odeny



Dr. Nirmal Choradia

Some of our current fellows




Dr. Princess Mark-Adjeli

NIH Hematology Oncology Fellowship



Where Recent Alumni Are Employed



Career Paths for Clinical Researchers – PEIP

Physician-Scientist Early Investigator Program (PEIP) – 3 Year, Pre-Tenure Track Position

- Assigned dedicated space, provided with an independent budget including travel and training funds, and given access to an extensive infrastructure
- Program participants must develop a research proposal within the first six months in collaboration with a mentor, participate in a course focusing on writing cancer grant applications, and participate in an NIH leadership course.
- Participants have the option to apply for an NIH Career Development Award (K mechanism) and complete the courses [Introduction to the Principles and Practice of Clinical Research](#), [Principles of Clinical Pharmacology](#), and [Ethical and Regulatory Aspects of Clinical Research](#).



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Haobin Chen, M.D., Ph.D.
haobin.chen@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Kazusa Ishii, M.D., M.P.H.
kazusa.ishii@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Nicholas D. Klemen, M.D.
nicholas.klemen@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Andra V. Krauze, M.D., FRCPC, DABR
andra.krauze@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Anandani Nellan, M.D., M.P.H.
anandani.nellan@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Naris Nilubol, M.D., F.A.C.S.
niluboln@mail.nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Padma Sheila Rajagopal, M.D., M.P.H., M.Sc.
sheila.rajagopal@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Ramya Ramaswami, M.B.B.S., M.P.H.
ramya.ramaswami@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Nitin Roper, M.D., M.Sc.
nitin.roper@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Samira M. Sadowski, M.D.
samira.sadowski@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Vassiliki Saloura, M.D. Ph.D.
valia.saloura@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Changqing Xie, M.D., Ph.D.
changqing.xie@nih.gov



PHYSICIAN-SCIENTIST EARLY INVESTIGATOR
Chen Zhao, M.D.
chen.zhao@nih.gov

Career Paths for Clinical Researchers – Staff Clinician



Dr. Christopher Pleyer



Dr. Rosa Nadal Rios



Dr. Jason Redman



Dr. Fatima Karzai

- Assistant Research Physician
- Associate Research Physician
- Senior Clinician



Dr. Jennifer Brudno



Dr. Lekha Mikkilineni

One path to becoming a clinical researcher



Dr. Yolanda Cruz

OBERLIN

COLLEGE & CONSERVATORY

Bachelor of Arts



Masters in Global
Public Health



Dr. Eric Houpt



Medical School



Dr. Rita Nanda



Internal Medicine
Residency



Dr. Thomas Uldrick



NATIONAL CANCER INSTITUTE
Center for Cancer Research

Fellowship



NATIONAL CANCER INSTITUTE
Center for Cancer Research


Faculty



NATIONAL CANCER INSTITUTE
Center for Cancer Research

The story of pomalidomide in Kaposi sarcoma

The story of pomalidomide in Kaposi sarcoma



The story of pomalidomide in Kaposi sarcoma

Journal of Clinical Oncology 2000 Jul;18(13):2593-602

Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma

By Richard F. Little, Kathleen M. Wyvill, James M. Pluda, Lauri Welles, Vickie Marshall, William D. Figg, Fonda M. Newcomb, Giovanna Tosato, Ellen Feigal, Seth M. Steinberg, Denise Whitby, James J. Goedert, and Robert Yarchoan

Blood (2011) 118 (11): 2970–2975

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Martha Q. Lacy,¹ Jacob B. Allred,² Morie A. Gertz,¹ Suzanne R. Hayman,¹ Kristen Detweiler Short,¹ Francis Buadi,¹ Angela Dispenziera,¹ Shaji Kumar,¹ Philip R. Greipp,¹ John A. Lust,¹ Stephen J. Russell,¹ David Dingli,¹ Steven Zeldenrust,¹ Rafael Fonseca,³ P. Leif Bergsagel,³ Vivek Roy,⁴ A. Keith Stewart,³ Kristina Laumann,² Sumithra J. Mandrekar,² Craig Reeder,³ S. Vincent Rajkumar,¹ and Joseph R. Mikhael³

The story of pomalidomide in Kaposi sarcoma

NIH U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾ PRS Login

Home > Search Results > Study Record Detail Save this study

Trial record 1 of 1 for: NCT01495598
Previous Study | [Return to List](#) | Next Study

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

ClinicalTrials.gov Identifier: NCT01495598

Recruitment Status: Active, not recruiting
First Posted: December 20, 2011
Last Update Posted: October 8, 2020

Sponsor:
National Cancer Institute (NCI)

Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.



Dr. Mark Polizzotto



Dr. Thomas Uldrick


VOLUME 34 · NUMBER 34 · DECEMBER 1, 2016

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Mark N. Polizzotto, Thomas S. Uldrick, Kathleen M. Wyvill, Karen Aleman, Cody J. Peer, Margaret Bevans, Irini Sereti, Frank Maldarelli, Denise Whitby, Vickie Marshall, Priscila H. Goncalves, Vikram Khetani, William D. Figg, Seth M. Steinberg, Jerome B. Zeldis, and Robert Yarchoan



The story of pomalidomide in Kaposi sarcoma

www.impactjournals.com/oncotarget/

Oncotarget, 2017, Vol. 8, (No. 31), pp: 50342-50358

Priority Research Paper

Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide

David A. Davis^{1,*}, Suraj Mishra^{1,*}, Holda A. Anagho¹, Ashley I. Aisabor¹, Prabha Shrestha¹, Victoria Wang¹, Yuki Takamatsu¹, Kenji Maeda¹, Hiroaki Mitsuya¹, Jerome B. Zeldis² and Robert Yarchoan¹

ONCOIMMUNOLOGY
2019, VOL. 8, NO. 2, e1546544 (16 pages)
<https://doi.org/10.1080/2162402X.2018.1546544>



ORIGINAL RESEARCH

OPEN ACCESS Check for updates

Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells

David A. Davis^{a*}, Prabha Shrestha^{a*}, Ashley I. Aisabor^a, Alexandra Stream^a, Veronica Galli^b, Cynthia A. Pise-Masison^b, Takanobu Tagawa^a, Joseph M. Ziegelbauer^a, Genoveffa Franchini^b, and Robert Yarchoan



The story of pomalidomide in Kaposi sarcoma

Pomalidomide combined with chemotherapy...



Dr. Thomas Uldrick



Dr. Ramya Ramaswami

[Journal of Clinical Oncology](#) > [List of Issues](#) > [Volume 38, Issue 15, suppl](#) >

SARCOMA

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.

[Ramya Ramaswami](#), [Kathryn Anne Lurain](#), [Anaida Widell](#), [Priscila Hermont Goncalves](#), [Irene Ekwede](#), [William Douglas Figg](#), [Cody J. Peer](#), [Ralph Mangusan](#), [Jomy George](#), [Seth M. Steinberg](#), [Vikram Khetani](#), [Denise Whitby](#), [Thomas S. Uldrick](#), [Robert Yarchoan](#)

Novel combination immunotherapy approaches...

NCI Protocol #: 10363
Local Protocol #: pending
ClinicalTrials.gov Identifier: TBD

TITLE: A Phase I Study of pomalidomide and nivolumab in patients with virus-associated malignancies with or without HIV


Coordinating Center: NCICCR / NCI Center for Cancer Research

Principal Investigator: Kathryn Lurain, MD, MPH
HIV and AIDS Malignancy Branch
National Cancer Institute

Immunomodulatory agents for new virus-driven cancers...

The screenshot shows the ClinicalTrials.gov website interface. At the top, it displays the NIH logo and the text "U.S. National Library of Medicine". Below this is the "ClinicalTrials.gov" logo. Navigation links include "Find Studies", "About Studies", "Submit Studies", "Resources", "About Site", and "PRS Login". The search results section shows "Home > Search Results > Study Record Detail" with a "Save this study" checkbox. The main content area displays "Trial record 1 of 1 for: NCT02911142" and navigation links for "Previous Study", "Return to List", and "Next Study". The study title is "Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma". At the bottom right, the "ClinicalTrials.gov Identifier: NCT02911142" is shown.

The story of pomalidomide in Kaposi sarcoma



Administrative
Corporate
Structure of
are HIV
C-0047
stitute. Twenty-eight patients (18 HIV-positive, 10
pomalidomide orally once daily on days 1 through 21 of
treatment or unacceptable toxicity. All HIV-positive
patients received antiretroviral therapy.

The HIV and AIDS Malignancy Branch



If I can be helpful to you in any way, please contact me!

email: kathryn.lurain@nih.gov

cell: 301-250-5156





NATIONAL CANCER INSTITUTE
Center for Cancer Research

ccr.cancer.gov